ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pralatrexate

Also written as “Pralatrexate Injection”, “Pralatrexate” and “Folotyn”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Cutaneous · Hematologic Neoplasms · Lymphoma, B-Cell, led by 3 companies.

Drug pagePralatrexate: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 19, 202319 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aurobindo Pharmaits history only122 open or runningphase 3since Sep 19, 2023Aug 14, 2006Feb 2027phase 1 · NCT07036133
Zydus Lifesciencesits history only40 open or runningphase 3since Aug 18, 2011Jan 24, 2003none ahead
Mundipharma30 open or runningphase 4since May 5, 2017Dec 4, 2013none ahead

Also a collaborator on its studies: Axis Clinicals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mundipharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2013First study: phase 2 study in Lymphoma, T-Cell, PeripheralFirst studyNCT02013362 · 25 enrolled · Japan
  2. Jul 26, 2016Phase 3 study in Lymphoma, T-Cell, PeripheralNCT03349333 · 85 enrolled · China
  3. May 5, 2017Phase 4 study in Lymphoma, T-Cell, PeripheralNCT03150602 · 22 enrolled · Taiwan

TargetBeta

DHFR →RFC1 →read by rule
“A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities”NCIt, by rule
“Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Studies

All 3 Mundipharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03150602Lymphoma, T-Cell, Peripheral · Taiwan4UNKNOWNDec 31, 202022
NCT03349333Lymphoma, T-Cell, Peripheral · China3CompletedJul 21, 201785
NCT02013362Lymphoma, T-Cell, Peripheral · Japan2CompletedDec 201525

How it is read

Names in the registry

  • “Pralatrexate Injection”, 9 entries
  • “Pralatrexate”, 4 entries
  • “pralatrexate”, 2 entries
  • “Folotyn”, 2 entries
  • “Folotyn and Leucovorin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.